Opaleye Management Inc.
In its 13F for Q1 2024 (holdings as of March 31, 2024, filed May 29, 2024), Opaleye Management Inc. reported 51 stock positions worth $455.6 million. Its top holding was Ocular Therapeutix (OCUL) at 13.3% of the portfolio, followed by Harrow (HROW, 11.4%) and TG Therapeutics (TGTX, 7.6%). Compared with Q4 2023, it opened 14 new positions, sold out of 8, added to 16 and reduced 15. The biggest buy was Ocular Therapeutix (OCUL, shares +10%) and the biggest sale Acelyrin (SLRN, shares −62%).
- Most Recent 13F
- Q2 2026
- Location
- BOSTON, MA
- CIK
- 0001595855
- Portfolio Value
- $455.6M (Q1 2024)
- SEC Filing
- 0001493152-24-021780 ↗ filed May 29, 2024
Holdings Value
Holdings 51 stocks · $455.6M
| OCUL Ocular Therapeutix Inc. | 13.29% | 6,653,138 | $60.5M | Add +9.6% |
| HROW Harrow Inc. | 11.38% | 3,920,600 | $51.9M | Add +2.6% |
| TGTX TG Therapeutics Inc. | 7.61% | 2,280,000 | $34.7M | Add +2.9% |
| KROS Keros Therapeutics Inc. | 5.34% | 367,500 | $24.3M | Add +2.8% |
| RYTM Rhythm Pharmaceuticals Inc. | 4.90% | 515,000 | $22.3M | Reduce -15.6% |
| CPRX Catalyst Pharmaceuticals Inc. | 3.51% | 1,004,355 | $16.0M | Reduce -20.1% |
| ARVN Arvinas Inc. | 2.99% | 330,000 | $13.6M | Add +25.1% |
| IOVA Iovance Biotherapeutics Inc. | 2.92% | 897,000 | $13.3M | No change |
| JSPR Jasper Therapeutics Inc. | 2.81% | 435,573 | $12.8M | New |
| EWTX Edgewise Therapeutics Inc. | 2.66% | 665,000 | $12.1M | Reduce -4.9% |
| APLT Applied Therapeutics Inc. | 2.64% | 1,770,000 | $12.0M | Add +62.0% |
| FDMT 4D Molecular Therapeutics Inc. | 2.41% | 344,123 | $11.0M | Add +11.6% |
| CDXS Codexis Inc. | 2.39% | 3,120,000 | $10.9M | Add +2.5% |
| TARA Protara Therapeutic Inc. | 2.37% | 2,692,594 | $10.8M | No change |
| SLRN Acelyrin Inc. | 2.34% | 1,580,000 | $10.7M | Reduce -61.9% |
| CRNX Crinetics Pharmaceuticals Inc. | 2.16% | 210,000 | $9.8M | Reduce -31.7% |
| ETON Eton Pharmaceuticals Inc. | 2.01% | 2,445,781 | $9.2M | Reduce -3.3% |
| TRVI Trevi Therapeutics Inc. | 2.00% | 2,645,000 | $9.1M | Add +4.3% |
| LYEL Lyell Immunopharma Inc. | 1.64% | 3,355,000 | $7.5M | New |
| NAMS Newamsterdam Pharma Co. NV | 1.64% | 315,388 | $7.5M | Add +18.8% |
| VTYX Ventyx Biosciences Inc. | 1.55% | 1,285,000 | $7.1M | Add +12.7% |
| NTLA Intellia Therapeutics Inc. | 1.54% | 255,000 | $7.0M | Add +157.6% |
| CMPX Compass Therapeutics Inc. | 1.38% | 3,170,000 | $6.3M | New |
| XOMA Xoma Royalty Corporation filed as XOMA CORP DEL | 1.32% | 250,000 | $6.0M | No change |
| LQDA Liquidia Corp. | 1.28% | 395,000 | $5.8M | Reduce -11.2% |
| PCVX Vaxcyte Inc. | 1.27% | 85,000 | $5.8M | Reduce -5.6% |
| NYXH Nyxoah SA | 0.95% | 320,000 | $4.3M | Reduce -7.2% |
| SVRA Savara Inc. | 0.93% | 855,000 | $4.3M | New |
| SYRS Syros Pharmaceuticals Inc. | 0.92% | 787,545 | $4.2M | Add +119.2% |
| URGN Urogen Pharma Ltd. | 0.89% | 270,000 | $4.0M | Reduce -15.6% |
| NRIX Nurix Therapeutics Inc. | 0.86% | 267,210 | $3.9M | New |
| RVNC Revance Therapeutics Inc. | 0.85% | 785,000 | $3.9M | New |
| RLMD Relmada Therapeutics Inc. | 0.77% | 759,000 | $3.5M | Reduce -13.4% |
| PTGX Protagonist Therapeutics Inc. | 0.72% | 112,700 | $3.3M | No change |
| ZNTL Zentalis Pharmaceuticals Inc. | 0.69% | 200,000 | $3.2M | New |
| ALLK Allakos LLC | 0.67% | 2,435,000 | $3.1M | New |
| GOSS Gossamer Bio Inc. | 0.63% | 2,440,109 | $2.9M | Reduce -18.2% |
| IBIO Ibio Inc. | 0.61% | 680,000 | $2.8M | New |
| VSTM Verastem Inc. | 0.55% | 211,400 | $2.5M | No change |
| ALGS Aligos Therapeutics Inc. | 0.35% | 1,630,000 | $1.6M | Add +25.7% |
| CNTX Context Therapeutics Inc. | 0.34% | 1,108,357 | $1.5M | Add +13.7% |
| PGEN Precigen Inc. | 0.30% | 947,500 | $1.4M | Reduce -6.4% |
| LRMR Larimar Therapeutics Inc. | 0.29% | 174,413 | $1.3M | Reduce -72.0% |
| FULC Fulcrum Therapeutics Inc. | 0.27% | 130,000 | $1.2M | No change |
| MOR Morphosys AG ADR | 0.26% | 65,000 | $1.2M | Reduce -55.2% |
| GKOS Glaukos Corp. | 0.18% | 8,576 | $809K | New |
| PMVP PMV Pharmaceuticals Inc. | 0.18% | 471,481 | $802K | New |
| BDSX Biodesix Inc. | 0.17% | 534,657 | $765K | Add +7.7% |
| RGLS Regulus Therapeutics Inc. | 0.11% | 170,308 | $490K | New |
| DSGN Design Therapeutics Inc. | 0.10% | 113,038 | $456K | New |
| RPTX Repare Therapeutics Inc. | 0.07% | 67,561 | $318K | New |
Other holdings (1): bonds, preferreds, convertibles and warrants · $3.2M (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| GOSSAMER BIO INC (GOSS 5 06/01/27) | NOTE 5.000% 6/0 · principal | 8,000,000 | $3.2M | No change |
Total filed on the 13F, all lines: $458.9M.
Portfolio Sells Q4 2023 → Q1 2024
| SLRN Acelyrin Inc. | Reduce -61.9% | 2.34% | −5.95 |
| IDYA Ideaya Biosciences Inc. | Sold out | 0.00% | −2.97 |
| RYTM Rhythm Pharmaceuticals Inc. | Reduce -15.6% | 4.90% | −2.62 |
| BHVN Biohaven Ltd. | Sold out | 0.00% | −2.29 |
| CPRX Catalyst Pharmaceuticals Inc. | Reduce -20.1% | 3.51% | −2.23 |
| ARQT Arcutis Biotherapeutics Inc. | Sold out | 0.00% | −1.70 |
| MRNS Marinus Pharmaceuticals Inc. | Sold out | 0.00% | −1.64 |
| ETON Eton Pharmaceuticals Inc. | Reduce -3.3% | 2.01% | −0.96 |
| JSPR Jasper Therapeutics Inc. | Sold out | 0.00% | −0.84 |
| CRNX Crinetics Pharmaceuticals Inc. | Reduce -31.7% | 2.16% | −0.77 |
| KALV Kalvista Pharmaceuticals Inc. | Sold out | 0.00% | −0.49 |
| LRMR Larimar Therapeutics Inc. | Reduce -72.0% | 0.29% | −0.47 |
| URGN Urogen Pharma Ltd. | Reduce -15.6% | 0.89% | −0.40 |
| STRO Sutro Biopharma Inc. Com SHS | Sold out | 0.00% | −0.35 |
| PCVX Vaxcyte Inc. | Reduce -5.6% | 1.27% | −0.24 |
| RLMD Relmada Therapeutics Inc. | Reduce -13.4% | 0.77% | −0.20 |
| KNSA Kiniksa Pharmaceuticals Ltd. | Sold out | 0.00% | −0.17 |
| LQDA Liquidia Corp. | Reduce -11.2% | 1.28% | −0.16 |
| MOR Morphosys AG ADR | Reduce -55.2% | 0.26% | −0.13 |
| GOSS Gossamer Bio Inc. | Reduce -18.2% | 0.63% | −0.10 |
| PGEN Precigen Inc. | Reduce -6.4% | 0.30% | −0.06 |
| NYXH Nyxoah SA | Reduce -7.2% | 0.95% | +0.52 |
| EWTX Edgewise Therapeutics Inc. | Reduce -4.9% | 2.66% | +0.61 |
Portfolio Buys Q4 2023 → Q1 2024
| OCUL Ocular Therapeutix Inc. | Add +9.6% | 13.29% | +6.03 |
| JSPR Jasper Therapeutics Inc. | New | 2.81% | +2.81 |
| APLT Applied Therapeutics Inc. | Add +62.0% | 2.64% | +1.66 |
| LYEL Lyell Immunopharma Inc. | New | 1.64% | +1.64 |
| KROS Keros Therapeutics Inc. | Add +2.8% | 5.34% | +1.53 |
| CMPX Compass Therapeutics Inc. | New | 1.38% | +1.38 |
| TRVI Trevi Therapeutics Inc. | Add +4.3% | 2.00% | +1.09 |
| SVRA Savara Inc. | New | 0.93% | +0.93 |
| NRIX Nurix Therapeutics Inc. | New | 0.86% | +0.86 |
| RVNC Revance Therapeutics Inc. | New | 0.85% | +0.85 |
| NAMS Newamsterdam Pharma Co. NV | Add +18.8% | 1.64% | +0.84 |
| VTYX Ventyx Biosciences Inc. | Add +12.7% | 1.55% | +0.80 |
| FDMT 4D Molecular Therapeutics Inc. | Add +11.6% | 2.41% | +0.73 |
| NTLA Intellia Therapeutics Inc. | Add +157.6% | 1.54% | +0.73 |
| ZNTL Zentalis Pharmaceuticals Inc. | New | 0.69% | +0.69 |
| ALLK Allakos LLC | New | 0.67% | +0.67 |
| IBIO Ibio Inc. | New | 0.61% | +0.61 |
| GKOS Glaukos Corp. | New | 0.18% | +0.18 |
| PMVP PMV Pharmaceuticals Inc. | New | 0.18% | +0.18 |
| SYRS Syros Pharmaceuticals Inc. | Add +119.2% | 0.92% | +0.17 |
| ALGS Aligos Therapeutics Inc. | Add +25.7% | 0.35% | +0.12 |
| RGLS Regulus Therapeutics Inc. | New | 0.11% | +0.11 |
| DSGN Design Therapeutics Inc. | New | 0.10% | +0.10 |
| ARVN Arvinas Inc. | Add +25.1% | 2.99% | +0.08 |
| RPTX Repare Therapeutics Inc. | New | 0.07% | +0.07 |
| CNTX Context Therapeutics Inc. | Add +13.7% | 0.34% | +0.04 |
| HROW Harrow Inc. | Add +2.6% | 11.38% | −0.08 |
| CDXS Codexis Inc. | Add +2.5% | 2.39% | −0.10 |
| BDSX Biodesix Inc. | Add +7.7% | 0.17% | −0.80 |
| TGTX TG Therapeutics Inc. | Add +2.9% | 7.61% | −2.53 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 58 | $1.1B | LQDA, ETON, HROW, IRON, URGN |
| Q1 2026 | 54 | $759.2M | HROW, LQDA, ETON, SLGL, RYTM |
| Q4 2025Amended | 54 | $757.9M | HROW, LQDA, ETON, RYTM, APGE |
| Q3 2025 | 42 | $702.7M | HROW, ETON, LQDA, RYTM, IMNM |
| Q2 2025Amended | 39 | $483.6M | HROW, ETON, IMNM, SNWV, LQDA |
| Q1 2025 | 43 | $438.3M | HROW, ETON, SNWV, LQDA, RYTM |
| Q4 2024 | 37 | $560.7M | HROW, TGTX, CDXS, ETON, OCUL |
| Q3 2024 | 42 | $591.4M | HROW, TGTX, OCUL, ARVN, CDXS |
| Q2 2024 | 49 | $430.0M | HROW, TGTX, OCUL, RYTM, KROS |
| Q1 2024Amended | 51 | $455.6M | OCUL, HROW, TGTX, KROS, RYTM |